Senolytics

Trial registry update: COMPLETED. No results reported in the supplied registry record.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

Trial registry update: COMPLETED. No results reported in the supplied registry record.

Trial registry update: WITHDRAWN. No results reported in the supplied registry record.

Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.

Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.

Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.

Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.

Trial registry update: WITHDRAWN. No results reported in the supplied registry record.

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

Trial registry update: COMPLETED. No results reported in the supplied registry record.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.

Trial registry update: TERMINATED. Results are posted in the registry; assessment pending.

Trial registry update: UNKNOWN. No results reported in the supplied registry record.

Trial registry update: SUSPENDED. No results reported in the supplied registry record.

Trial registry update: UNKNOWN. No results reported in the supplied registry record.

Trial registry update: UNKNOWN. No results reported in the supplied registry record.

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

Trial registry update: ENROLLING_BY_INVITATION. No results reported in the supplied registry record.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

This systematic review examined mTOR signaling as a hub coordinating aging processes across genetic, experimental, and translational studies. In model organisms, mTOR pathway inhibition shows causal effects on lifespan regulation, whereas human data remain predominantly observational and associative. The review identifies mTOR as an integrative node linking multiple aging hallmarks and notes that major geroprotective interventions—including autophagy activation, dietary changes, physical activity, and senotherapeutics—partly converge on but also diverge from mTOR pathway modulation.

This systematic review synthesizes evidence linking chronic low-grade inflammation (inflammaging) driven by senescent cells to concurrent skeletal aging and cognitive impairment. The authors propose that SASP-derived cytokines and inflammatory pathways (NF-κB, NLRP3) simultaneously drive bone resorption and neuroinflammation through the bone-brain axis, and discuss candidate interventions including senolytics, though they explicitly note most mechanisms rest on preclinical models or single cohorts lacking independent human validation.

This is a review article that synthesizes evidence on the pathophysiology of sarcopenia, focusing on early changes in the muscle microenvironment rather than end-stage myofiber atrophy. The authors identify key mechanisms including dysregulated immunity, cellular senescence, satellite cell dysfunction, mitochondrial dysfunction, and impaired proteostasis. The review proposes that targeting these early alterations through exercise, nutrition, anti-inflammatory strategies, senescent cell clearance, and mitochondrial support may offer more effective therapeutic approaches than interventions addressing only late-stage muscle loss.

This animal study investigated cellular senescence in TDP-43Q331K mice, a genetic model of amyotrophic lateral sclerosis. Researchers treated mice with dasatinib and quercetin (senolytics) and found improvements in motor behavior, neuromuscular function, reduced axonal damage measured by plasma neurofilament light chain, enhanced motor cortex excitability, and preserved layer V neuron counts compared to controls.

This is a review article examining the role of senescence-associated extracellular vesicles (SA-EVs) in skin aging and dysfunction. The authors describe how SA-EVs are secreted by senescent cells and carry proinflammatory cargo that promotes further senescence, impairs wound healing, and contributes to chronic wounds, diabetic ulcers, scarring, and skin aging. The review discusses potential therapeutic approaches including senolytics, senomorphics, stem cell-derived EVs, and biomaterial-assisted systems.

This narrative review synthesized peer-reviewed literature on necroptosis, cellular senescence, and renal tubulointerstitial fibrosis, searching PubMed, Web of Science, and Embase through July 2026. The authors describe a proposed mechanistic continuum where mitochondrial DNA released from necroptotic tubular cells drives glycolytic reprogramming and a senescence-associated secretory phenotype that amplifies fibrosis. Senolytics are mentioned among existing targeted strategies showing "preclinical efficacy" but the review does not report actual senolytic trial data, effect sizes, or clinical translation success.

In vitro study testing two Lavandula essential oils on etoposide-induced senescent human skin fibroblasts. L. stoechas subsp. luisieri reduced multiple senescence markers (β-galactosidase activity, nuclear alterations, SASP secretion, cell cycle inhibitor expression, and ultrastructural changes) at concentrations as low as 6.25 μg/mL, with greater efficacy than L. pedunculata.

This in vitro study used high-content cell imaging and transcriptomics to characterize senescence mechanisms and distinguish between replicative and chemically induced senescence, as well as differentiate senescence from quiescence. The authors also characterized how senolytics respond in this system.

Researchers studied the LMNA-CK2α-STING signaling axis in aging using mouse models of progeria. Pharmacologic STING inhibition (H-151) in vivo rescued progeroid phenotypes including bone density loss and multi-tissue senescence, and extended lifespan. The authors found that controlled attenuation of STING signaling was more effective than complete STING ablation.

An in vitro study examined how Mycobacterium abscessus infection induces senescence in alveolar macrophages through DNA damage signalling, which then spreads to neighboring cells via paracrine SASP secretion. Treatment with the senolytic drug Navitoclax selectively eliminated senescent cells and reduced bacterial burden to levels similar to antibiotic treatment.

This systematic review examined how biological sex and aging shape molecular mechanisms in ischemic stroke, emphasizing sex-specific cell death pathways, mitochondrial dysfunction, and NAD+-sirtuin signaling. The authors describe how premenopausal females show caspase-dependent apoptosis while males exhibit PARP-1-mediated parthanatos, and how postmenopausal females lose neuroprotective advantages due to estrogen receptor changes and mitochondrial decay. The review proposes precision medicine approaches including ER-alpha modulators, NAD+ precursors, and senolytic combinations tailored to sex and reproductive stage.

Open-label pilot study in patients with idiopathic pulmonary fibrosis examining intermittent oral dosing of dasatinib plus quercetin over 3 weeks. The intervention aimed to reduce pro-inflammatory cells and cellular senescence markers. The study assessed safety, tolerability, and effects on inflammatory biomarkers, with hypothesized preservation of functional outcomes.

This observational study examined whether the senolytics quercetin and dasatinib affected epigenetic aging rates in healthy individuals over 16 weeks. Participants underwent epigenetic age testing at baseline, the 8-week midpoint, and after 16 weeks. The abstract does not report what effects were actually found.

This was a double-blind randomized controlled trial of 60 patients with mild to moderate knee osteoarthritis, comparing two different fisetin dosing regimens against placebo over 3 months. The trial aimed to assess whether fisetin reduced pain and functional impairment, and evaluated changes in senescent cell activity and cartilage degradation biomarkers. No results are reported in this abstract.

This pilot study investigated whether a combination of dasatinib and quercetin (D+Q) penetrates into the brain via cerebrospinal fluid in older adults with early Alzheimer's disease. The study was designed as a proof-of-concept to evaluate drug bioavailability in the brain, as prior evidence showed this combination affects dying cells in other chronic illnesses and in mouse models of Alzheimer's disease. No efficacy outcomes on Alzheimer's symptoms were reported in this preliminary phase.

This randomized, double-blind, placebo-controlled trial enrolled 60 patients with symptomatic knee osteoarthritis and effusion-synovitis at a single Egyptian center. Participants received either quercetin plus fisetin alone (n=20), quercetin plus fisetin plus glycyrrhizin (n=20), or placebo (n=20) in intermittent dosing cycles over 15 weeks. Primary outcomes were change in knee pain (VAS) and effusion-synovitis volume on MRI; secondary outcomes included WOMAC scores, cartilage changes on T2 relaxation imaging, medication use, and quality of life measures.

COVFIS-HOME tested whether fisetin, a senolytic drug, could reduce complications in COVID-19 patients. The phase 2 placebo-controlled pilot study enrolled at-risk outpatients, but the abstract does not report sample size, effect sizes, or specific findings on whether fisetin reduced complications.

This prospective, randomized, double-blind, active-control trial evaluated whether a senolytic agent (Fisetin) and an anti-fibrotic agent (Losartan), used independently and in combination, could improve the effect of autologous bone marrow aspirate concentrate (BMAC) injection into osteoarthritic knees. The abstract provided reports the trial design and intervention structure but does not report results, efficacy outcomes, or safety findings.

This was a pilot RCT investigating whether the senolytic agent fisetin, combined with platelet-rich plasma (PRP) and losartan, could improve outcomes in patients undergoing hip arthroscopy for femoroacetabular impingement and labral tear. The study aimed to assess clinical outcomes, safety, and markers of senescence and fibrosis, but the abstract reports study objectives and design only—no results are presented.

This phase 2 RCT tested whether senolytic drugs reduce senescent cells and alter bone metabolism markers in elderly women over 20 weeks. The study was open-label and single-center. The abstract states the objective but does not report the findings, sample size, effect sizes, or specific outcomes achieved.

A Phase II randomised controlled trial evaluated tislelizumab (anti-PD-1 antibody) combined with dasatinib and quercetin (senolytics) as neoadjuvant therapy before surgery in patients with head and neck squamous cell carcinoma. The trial assessed efficacy and safety of this combined immunotherapy-senolytic approach.

This Phase I/II randomized, double-blind, placebo-controlled trial tested the senolytic drug fisetin in patients with mild to moderate osteoarthritis. The abstract reports testing for safety and efficacy, but does not present actual efficacy results or sample size details.

This pilot study tested the safety and feasibility of intermittent dasatinib and quercetin dosing in older adults at risk of Alzheimer's disease. The study aimed to evaluate whether the treatment might improve cerebral blood flow, mobility, and cognition. Results of the trial outcomes are not reported in the abstract.

This was an open-label pilot study of a senolytic supplement in adults aged 45–79 conducted entirely remotely over 7 days. Participants provided blood samples via at-home finger-prick kits at baseline and day 7, and completed health surveys at baseline, day 3, and day 7. The abstract does not report any findings, effect sizes, or outcomes.

This is a registered randomized clinical trial protocol testing a combined intervention after arthroscopic meniscus repair: oral senolytic fisetin plus a real-time biofeedback program to restore joint loading and return to activity. The study aims to address meniscus injury recovery and reduce posttraumatic osteoarthritis risk in a population with high prevalence of meniscal procedures.

This preclinical study used mice exposed to 20 Gy cardiac irradiation to investigate radiation-induced atrial fibrillation. Irradiation triggered DNA damage, cellular senescence, and atrial remodeling through GATA4-NF-κB signaling. Treatment with the senolytic combination dasatinib and quercetin suppressed this pathway, reduced senescence markers, and reversed atrial remodeling with decreased susceptibility to atrial fibrillation.

This was a Phase 2 placebo-controlled randomized trial testing fisetin, a senolytic drug, in older adults with COVID-19 in nursing homes. The study aimed to determine whether fisetin could prevent disease progression and reduce inflammatory complications, though the abstract does not report the results, sample size achieved, or magnitude of any effects observed.

This was a Phase 2 placebo-controlled randomized trial testing whether fisetin, a senolytic drug, could prevent disease progression and alleviate inflammatory complications in hospitalized COVID-19 patients. The abstract states the study tested this hypothesis but does not report specific results, effect sizes, or outcomes.

This is a pilot randomised controlled trial designed to test whether intermittent fisetin treatment improves vascular endothelial function and reduces aortic stiffness in older adults. The trial aimed to explore potential mechanisms including mitochondrial oxidative stress, cellular senescence, and SASP factors. No results or findings are reported.

This RCT examined whether senolytic therapy (dasatinib and quercetin given orally every two weeks for three months) is safe and feasible in adults aged 50-85 with secondary progressive MS who were not on disease-modifying therapy and had progressive symptoms. Participants were followed for one year to assess treatment effects on physical and cognitive function. No results of the trial are provided in this abstract.

This randomized controlled trial compared senolytics, lifestyle intervention, and placebo in older obese participants. Researchers performed baseline and post-intervention biopsies of abdominal adipose tissue for single-nuclei RNA sequencing analysis and measured metabolic outcomes including insulin sensitivity, glucose tolerance, and beta-cell function. The abstract provided does not report the study's primary results or findings.

A Phase II randomized controlled trial evaluated senolytics in older adults with amnestic mild cognitive impairment or early-stage Alzheimer's disease who were tau PET positive. The study assessed safety, feasibility, and efficacy of the intervention. Specific efficacy results, sample size, and effect sizes were not reported in the available material.

A double-blind randomised controlled trial examined whether the senolytic combination of dasatinib plus quercetin could reduce liver fibrosis in people with biopsy-proven non-alcoholic fatty liver disease (NAFLD). The study was designed as a proof-of-principle investigation but no sample size, effect size, or outcome results are provided in the material supplied.

Pilot randomized trial of 34 people with peripheral artery disease assigned to fisetin or placebo. The trial tested whether fisetin would reduce senescent cell markers in blood and tissue and improve 6-minute walk distance. The abstract reports the study design and proposed analyses but does not report actual results or whether fisetin affected walking distance, senescent markers, or inflammatory markers.

This pilot open-label study examined dasatinib plus quercetin, a combination selected for senolytic properties, in older individuals with depression or schizophrenia. The study assessed effects on physiological aging markers. No results, effect sizes, or sample size details were reported in the abstract.

SEN-SURVIVORS is an open-label pilot trial testing two senolytic regimens (dasatinib plus quercetin, and fisetin alone) in adult survivors of childhood cancer. The study aimed to measure changes in walking speed and blood senescent cell markers (p16^INK4a) at 60 days, with extended follow-up at 150 days. The abstract describes the study design and objectives but reports no results, efficacy measures, or outcomes.

The SENIOR Trial is a randomised controlled trial designed to test senolytics and antioxidant therapy for osteoporosis, framed as a disease of accelerated skeletal aging driven by senescent cell accumulation. The abstract does not report sample size, effect sizes, outcomes, or findings.

AFFIRM was a phase 2 randomized placebo-controlled trial testing fisetin (a senolytic) in older women with gait disturbance. The study aimed to evaluate effects on insulin resistance markers, inflammation, bone resorption, and physical dysfunction. Specific results were not reported in the provided abstract.

This systematic review examines the molecular mechanisms orchestrating cellular senescence, including the p53/p21 and p16/RB pathways, mitochondrial stress, and SASP programs, and how these are altered across cancer, metabolic, skeletal, and degenerative diseases. The authors discuss emerging theranostic strategies combining detection and intervention—such as enzyme-activatable prodrugs targeting senescence markers, smart nanocarriers, and engineered immune cells—alongside new methods for quantifying senescent burden in vivo.

This systematic review examined pharmacological interventions targeting aging pathways, including metformin, from literature published January 2010–May 2026. Metformin and rapamycin had among the most extensive preclinical and translational evidence, but the review found that clinical evidence for broadly applicable geroprotection remains limited. The authors emphasize a substantial gap between mechanistic plausibility and clinically validated geroprotection in humans.

ALSENLITE was an open-label pilot study evaluating the safety and feasibility of dasatinib and quercetin (senolytics) in subjects with mild cognitive impairment or Alzheimer's disease. The abstract reports the study design and objective but does not report results, sample size, or effect sizes.

This phase II randomized controlled trial tested fisetin (a dietary compound found in strawberries) combined with exercise against placebo for preventing frailty in breast cancer survivors. The trial was designed to evaluate whether fisetin could eliminate senescent cells—aged cells that stop dividing but persist in tissues—which are hypothesized to contribute to frailty through inflammatory pathways.

This is a phase II, multicenter randomized trial testing different doses of the senolytic drug fisetin in older patients with sepsis. The primary outcome is a composite score of cardiovascular, respiratory, and renal organ failure at 1 week. No results are reported in this abstract—only the study design, hypothesis, and intended outcomes are described.

This Phase II randomized controlled trial tested dasatinib plus quercetin (a senolytic combination) versus placebo in 80 people with HIV aged 50 or older who were frail or prefrail and virally suppressed on antiretroviral therapy. Participants received six cycles of the drug or placebo over 12 weeks (2 days on, 12 days off pattern), then were followed for another 12 weeks. The abstract does not report the results or whether physical function improved.